CNMDCONMED Corporation

Healthcare

$44.43-11% 1Y

$44.43

$32.1152 weeks$51.88

Is it safe?

Good

Strong, no red flags: a safe balance sheet and clean books.

2 good, 3 neutral, 1 without data

SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality5 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Credit gradeAderived · Jun 30, 2026

Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.

Drawdown risk44% volderived · Oct 9, 2026

Moderate price swings, typical volatility. Worst drawdown -79% · now 14% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitymiddle of the market

Max drawdownbehind 72% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can CNMD take a bad year?

CONMED Corporation carries $797M of net debt at 6.07× EBITDA: a heavy load to carry through a bad year.

$797M

Net debt · as at Q2 2026 · over four years of earnings before interest, tax and depreciation, heavy

Net debt / EBITDA: 6.07×
Net debt / EBITDA · 4.28× a year ago · the load is going up
Altman Z-score: 1.76
Altman Z-score · distress zone, below 1.8
Interest cover: 3.69×
Interest cover · operating profit covers the interest bill, with room to spare